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optimizing chronic respiratory disease (CRD) medication
adherence with a view to improving clinical outcomes and alle-
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that high-cost add-on therapies only be considered in patients
with severe disease who have persistent symptoms and/or exac-
erbations despite optimized treatment with high-dose controller
medications and treatment of modiﬁable risk factors.2 This
requirement for optimized therapy as a prerequisite to asthma
treatment escalations is of increasing relevance as evermore high-
cost biological therapies with narrow therapeutic margins are
expected to be licensed for CRD. Use of such novel therapies
must be targeted at patients with true unmet need to maximize
their cost-effectiveness.
Yet it is too simplistic to simply call for “good adherence” in
all patients across all therapies. Once the beneﬁt-risk ratio of a
treatment is shown to be positive, the ultimate goal of the
health care professional, payer, and patient should be to achieve
“efﬁcient use” of treatment, that is, use that maximizes treat-
ment beneﬁt while minimizing any potential risk of harm.
Efﬁcient use will vary between patients (eg, depending on their
phenotype) and between therapies (eg, depending on their
pharmacokinetic proﬁle). Moreover, there is a wide range of
real-life factors that can impair efﬁcient use of therapy and
resultant clinical outcomes.3 Such issues include limited
comprehension or recognition (among patients and/or their
health care professionals) of the importance and value of efﬁ-
cient use,4-6 medication beliefs and side-effect concerns, stigma
around inhalers, particularly in CRD where inhaled therapies
make up the backbone of licensed treatment, and device usage
challenges.7-9 Thus, interventions targeting “efﬁcient use” of
therapies must optimize adherence within the context of its
indicated use, prescribed use, and tailored to the characteristics
and requirements of the target patient. They must also furnish
patients with the information they require to make appropriate
decisions about their use of therapy, in a context of shared
decision making (SDM). With reference to the physician-
patient encounter, SDM has been deﬁned as being “interac-
tional” in nature.10 It is a process of 2-way information ex-
change and has the deﬁning characteristic of deliberation at its
core (ie, between the physician and the patient or potential
others). Both/all parties involved work toward reaching an
agreement and have an investment in the ultimate decision
made. Thus, the SDM philosophy emphasizes shared patient-
physician participation at every step of the decision-making
process. When fully realized in clinical practice, SDM can
notably reduce patients’ anxiety and decisional conﬂict, and
improve satisfaction and medication adherence.11
An important prerequisite to the development of successful,
scalable adherence interventions is the deﬁnition of clear adher-
ence concepts and evaluation tools such that adherence behaviors
can be accurately deﬁned and characterized, and opportunities to
intervene identiﬁed. In turn, this requires development, docu-
mentation, and use of standardized adherence deﬁnitions and799
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of combining distinct adherence behaviors (initiation of medi-
cation, implementation of the prescribed regimen and persistence
with it) under one encompassing term has resulted in barriers to
synthesizing adherence evidence and replicating and validating
previous studies and substantial research inefﬁciencies. In the
absence of a consensus vocabulary to ensure speciﬁcity of the
adherence research question, selection of appropriate research
methodologies, and clear reporting within adherence research,
pooling evidence across the research community and identifying
gaps in the evidence base has been a longstanding challenge. The
Ascertaining Barriers to Compliance taxonomy developed by
Vrijens et al12 is an important step toward this, distinguishing
between major concepts in adherence and standardizing termi-
nology, such that common approaches, deﬁnitions, and out-
comes can be consistently applied across studies and health
programs, with greater comparability and efﬁciency.
Five articles13-17 within this themed issue derive from a 1-
day adherence expert panel meeting held by the Respiratory
Effectiveness Group at the time of the 2015 European Asthma
Allergy and Clinical Immunology Annual Congress. For more
information about the Respiratory Effectiveness Group, visit
their Web site at www.effectivenessevaluation.org. The meeting
brought together world experts in asthma and chronic
obstructive pulmonary disease (COPD) and in adherence and
outcomes research. The multidisciplinary group set out to
explore the following: what is meant by adherence in respira-
tory medicine, how it is currently measured, and how it can be
positively affected. Through an examination of a number of
wide-ranging and complex adherence-related issues and con-
cepts—macro- (eg, health care system), meso- (eg, physician/
practice), micro- (individual patient), and their interaction and
mediators—the attendees (here coauthors) provide a snapshot
of current knowledge in respiratory adherence and point to
future needs to enable the ﬁeld to progress in a uniﬁed and
efﬁcient manner.
Vrijens et al’s article, “What we mean when we talk about
adherence in respiratory medicine,” revisits the authors’ Ascer-
taining Barriers to Compliance taxonomy, which deﬁnes a
temporal sequence of steps a patient must undertake to be
deﬁned as “adherent to treatment”: initiation, implementation,
and persistence.13 In this instance, the steps are considered in the
context of asthma and COPD. Behavioral determinants of
adherence are considered across these steps as are measurement
and assessment methods. The authors also touch on the clinical
realities of treatment interruptions and variations in drug expo-
sure that occur in real-world CRD management. Although
epidemiological research has traditionally used concepts of
“treatment episodes” and “treatment gaps” to reﬂect such clinical
realities, in variable conditions such as asthma (where symptoms
often drive the use of therapy) there is a need to reach consensus
on clinically meaningful deﬁnitions of treatment gaps to help
differentiate periods of nonimplementation from nonpersistence
and to model outcomes accordingly.
Dima et al’s article, “Mapping the asthma care process:
implications for research and practice,” outlines an asthma care
model developed by the ASTRO-LAB research group following
rigorous literature reviews and qualitative interviews.14 The model
offers a novel theoretical contribution to asthma management,
mapping for the ﬁrst time the sequence of treatment events, from
diagnosis to treatment prescription, drug exposure, asthma triggerexposure, and health outcomes. It also includes the relationships
between these components and moderators, including patient
behaviors (medication adherence, symptom monitoring, man-
aging triggers, and exacerbations) and health care professional
behaviors (medical care and self-management support). Themodel
details the major care events that affect adherence and, in its visual
depiction of the relationships between these events, identiﬁes
targets for effective adherence interventions. In this issue, it is also
used by Braido et al,15 Costello et al,16 and van Boven et al17 to
highlight the focus of their respective articles—each a more
concentrated examination of a particular element within the
macro-level care management model.
Braido et al’s article, “‘Trying, but failing’ - the role of inhaler
technique and mode of delivery in respiratory medication
adherence” isolates the moderator “Adherence—regular and
correct inhaler use” within the patient/carer domain of the
model.15 The authors focus on how modes of medication de-
livery can affect medication adherence, particularly adherence to
inhaled therapies that are the backbone to asthma and COPD
management. Through their review of the challenges posed by
different inhaler device types, multiple devices, and mixed device
use (for reliever and controller therapies), the authors illustrate
the myriad of research challenges and opportunities that key
elements of the asthma care model represent as well as the many
management considerations clinicians face (eg, device selection,
training, and education) when seeking to promote best use of
available therapies to their patients.
Focusing on “Determinants of patient behaviors” in the
asthma care model, Costello et al’s article, “The seven stages of
man: the role of developmental stage on medication adherence
in respiratory diseases,” skillfully illustrates the wide-ranging
implications that just one (time-varying) patient characteristic
can have on adherence.16 The authors consider adherence
determinants in both the lower and upper ends of the age
spectrum, from young patients with pediatric asthma to elderly
patients with COPD and possible cognitive impairment. In
particular, the authors call for greater research into the adherence
determinants and interventions in adolescents and elderly pa-
tients, noting the frequent gaps in access to effective adherence
support in elderly patients in light of cognitive and develop-
mental changes and the potential disruption in care continuity
faced by children transitioning to adult services.
Finally, van Boven et al’s article, “Enhancing respiratory
medication adherence: the role of health care professionals and
cost-effectiveness considerations,” considers determinants of
respiratory medication adherence from the perspective of health
care professionals and payers.17 The authors provide practical
suggestions for clinicians and pharmacists to intervene to
improve medication adherence in asthma and COPD. Exam-
ples of effective primary care interventions are shared and
standard approaches to health economic evaluations of such
interventions are explained, highlighting inherent differences in
model assumptions for asthma versus COPD. The authors also
outline some mechanisms (eg, intervention targeting) by which
cost-effectiveness ratios for different interventions can be opti-
mized to improve the probability of positive reimbursement
decisions, system-wide implementation, and resultant health
beneﬁts.
Optimized medication adherence is a central pillar of
effective CRD management. It equates to efﬁcient use of
available therapies such that outcomes are maximized and risks
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wide range of adherence determinants that exist within real-life
CRD management. Within this complex mix of determinants
and moderators of adherence behaviors there exist great
opportunities to adopt and implement standardized research
approaches to improve shared knowledge and understanding in
the ﬁeld. In clinical practice there is also a wealth of oppor-
tunities for health care professionals to intervene to optimize
patients’ adherence behaviors by taking time to ask targeted
questions, try to understand the challenges (real or perceived)
they face when prescribed CRD therapies, and work closely
with patients across the adherence pathway to address barriers
or concerns. Like all clinical ﬁelds, adherence research and
clinical practice interventions continue to evolve and now
face an era of increasing access to digital monitoring and
technology-based solutions that will offer opportunities to
monitor and characterize existing adherence behaviors and to
prompt and promote beneﬁcial changes.18 The optimum role
of such tools is yet to be determined, and is likely to change
between patients, diseases, and disease stages, but they will be
an addition to the clinician’s armamentarium. Irrespective,
considerate and tailored use of available adherence in-
terventions (whether high-, low-, or no-cost; digital or human)
will remain the key to their successful implementation and
realization of their full beneﬁt for patients, health care
professionals, and health systems alike.REFERENCES
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